Targeted radiation after surgery for meningioma that is intermediate-risk or has returned
Tests precise, shorter-course radiation after surgery in adults with meningioma.
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Registry title
- Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
- Status
- Recruiting
- People taking part
- 23 people, planned
- Started
- 13 Dec 2024
- Expected to end
- 30 Sept 2029
- Type of study
- Interventional
- Treatments tested
- Hypofractionated Stereotactic Radiosurgery (SRS)
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- Record updated
- 26 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who recently had surgery to remove a grade 2 meningioma, or a grade 1 meningioma that came back. They will get short-course, precisely aimed radiation (hypofractionated stereotactic radiosurgery).
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Newly diagnosed WHO grade 2 meningioma, or WHO grade 1 meningioma that came back on scans. The whole tumor must have been removed (Simpson grade I-III) within 180 days of joining. People must be fully active or able to care for themselves (ECOG 0 or 1, Karnofsky 70 or higher).
- Earlier treatment
- Surgery to remove the meningioma within 180 days of joining. Brain scans (MRI) before and after surgery are needed. No earlier radiation to the head overlapping the area to be treated.
- Biomarker or test result
- Tissue test confirming the meningioma grade. For grade 1 tumors that came back, the latest surgery must show WHO grade 1.
Main reasons for not taking part
- 3 or more meningiomas, or disease that has spread
- Tumor within 2mm of the optic nerves or brainstem
- Another active cancer, or past cancer without remission for at least 2 years (some exceptions)
- Pregnancy
- Uncontrolled seizures (more than 3 disabling seizures per day on seizure medicine)
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age >+ 18 years at time of study entry
- Ability to understand and the willingness to sign a written informed consent document
- Histologic diagnosis of newly diagnosed World Health Organization (WHO) grade 2 or recurrent WHO grade 1 meningioma. With regard to recurrent WHO grade 1 meningioma, participants must present with radiographic evidence of recurrence, and have a histologic diagnosis of WHO grade 1 meningioma at the most recent resection; Note: For participants diagnosed outside of University of California San Francisco (UCSF), re-review of pathology at UCSF is strongly encouraged. Hematoxylin and eosin (H\&E) slides will be reviewed by UCSF pathologists
- Participants must have undergone a gross-total surgical resection as deemed by their neurosurgeon (Simpson grade I-III resection), using all available information which can include post-operative MRI, of a meningioma within 180 days of enrollment
- Participants must have a pre-operative MRI
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky score of 70 or higher)
- Participants must have post-operative MRI indicating anatomy suitable for hypofractionated radiosurgery, as reviewed by the Radiation Oncology co-principal investigators (PIs)
Who cannot take part
- Concurrent participation in another clinical study with an investigational product unless it is an observational (non-interventional) study or the follow-up period of an interventional study
- Participants who have had previous intracranial radiotherapy overlapping with the area that would be targeted for stereotactic radiosurgery by this study
- Extensive multifocal (3 or more meningiomas) or metastatic disease
- Participants with another active primary malignancy or history of previous malignancy (except non-melanoma skin cancers, low and intermediate risk prostate cancers, and in situ cancers such as bladder, gastric, colon, cervical/dysplasia, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period
- Any underlying medical or psychiatric condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results
- Participants with uncontrolled seizures, defined as greater than 3 disabling seizures per day while on anti-epileptic drugs
- Participants with tumors within 2mm of the optic apparatus or brainstem will be excluded
- Female participants who are pregnant
Where in United States
- University of California San FranciscoSan Francisco, United StatesContact: Francim AguilarTaking people
About the trial
What the trial wants to find out
This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back after a period of improvement (recurrent). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Hypofractionated stereotactic radiosurgery may be safe, tolerable, and effective in treating patients with grade II or recurrent grade I meningiomas after surgical resection.
The group in the trial
- Hypofractionated Stereotactic Radiosurgery (SRS)Treatment being tested
Participants undergo hypofractionated stereotactic radiosurgery over 15-30 minutes QD on days 1-5 in the absence of disease progression or unacceptable toxicity.
Treatment: Hypofractionated Stereotactic Radiosurgery (SRS), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Pilot Trial of Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma (SRS-AIM)
- Plain-language title
- Targeted radiation after surgery for meningioma that is intermediate-risk or has returnedGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 26 August 2026